Leadless pacing is an emerging technology with the potential to significantly improve outcomes associated with the need for long-term pacing. Specifically, the major advantage of leadless systems is abolishing the need for transvenous leads and subcutaneous pockets, both of which account for most adverse events associated with traditional pacemakers. Two leadless pacemakers are currently available: the Nanostim (leadless cardiac pacemaker [LCP]) device (St. Jude Medical, Sylmar, California) and the Micra Transcatheter pacing system (Medtronic, Minneapolis, Minnesota). These 2 pacemakers have shown promising results in clinical trials. In conclusion, in this review we summarize the results of the 2 investigational device exemption trials and compare the pros and cons of these devices to traditional transvenous pacemakers.
Copyright © 2016 Elsevier Inc. All rights reserved.